RubrYc Therapeutics, Inc., a company that conducts preclinical biotherapeutic research into epitope-selective therapies, announced a collaborative research collaboration and licensing agreement with Zai Labs, Inc. in the use of the MEMs (Meso-scale Engineered Molecules) platform, used to identify monoclonal antibodies with enhanced biological function for an undisclosed oncological target.

Under the terms of the agreement, RubrYc and Zai Labs will work together to single out product candidates using RubrYc's Discovery Engine, which uses machine learning technology and structured data to identify antibodies that bind to subdominant epitopes and exhibit variable activity. Once the licensing option is implemented, Zai Labs would obtain exclusive worldwide rights to develop and commercialize the products resulting from this research collaboration.

RubrYc Therapeutics, Inc. will be paid upfront and entitled to receive future milestones of research, development and commercialization for each candidate, along with a margin on the net international sales of each product. The financial terms of the contract were not disclosed.

Dr. Isaac Bright, CEO, stated: “We are delighted that Zai Labs has selected RubrYc Discovery Engine as a solution to identify biological drugs to combat the most challenging oncological conditions. We look forward to working with Zai Labs, hoping to accelerate their research by identifying epitope-specific antibodies with different modes of action. Zai Labs expertise in the oncology field complements our commitment to deliver cutting edge therapies with breakthrough potential for patients in greatest need ”.

RubrYc Therapeutics, Inc.

RubrYc Therapeutics, Inc. is a biotechnology company that uses proprietary solutions in the field of machine learning and computational biology to discover epitope-selective mono- and bispecific antibodies. Drawing inspiration from the latest advances in molecular library synthesis, mass parallel screening and computation, the company is paving the way for the information-driven search for therapeutic antibodies. RubrYc Therapeutics, Inc. uses MEMs Discovery Engine technology to instantly identify a significant number of antibodies with unique properties in response to approved and demanding therapeutic targets. The company was established as a result of the separation from HealthTell, Inc. in 2018, to accelerate the discovery of biotherapeutics and establish partnerships with major pharmaceutical companies that share its mission to expand therapeutic options and improve the treatment efficacy of cancer patients. RubrYc is backed by institutional investors including Third Point Ventures, Paladin Capital Group, Vital Venture Capital and Hayan Health Networks. The company is headquartered in San Carlos, California.

For more information, visit www.rubryc.com .

The original text in the source language is the official, valid version of this notice. The text of the translation is for indicative purposes only, has been prepared solely to facilitate the understanding of the notice and should be interpreted in relation to the source text, which is the only version to have legal effect.

Contacts
Isaac J. Bright, MD
CEO of
RubrYc Therapeutics, Inc.
info@rubryc.com

 

Source: businesswire.com

Report Abuse